Key result
Severe obesity linked to ~254% higher bleeding risk compared to obesity after AF ablation.
Why the study?
Obesity drives and aggravates atrial fibrillation and significantly impacts treatment approaches by influencing the pharmacokinetics of antiarrhythmic drugs and anticoagulation regimes.
Does severe obesity compared to moderate obesity affect ablation success and post-interventional anticoagulation outcomes in patients undergoing catheter ablation for atrial fibrillation?
Cohort (n=325)
No
Does severe obesity compared to moderate obesity affect ablation success and post-interventional anticoagulation outcomes in patients undergoing catheter ablation for atrial fibrillation?
Severe obesity does not significantly impact AF ablation success or thromboembolic risk compared to moderate obesity, but is associated with a higher risk of bleeding events, suggesting careful consideration of post-ablation anticoagulation duration.
Answers are grounded in this paper and cite their sources.
Severe obesity was associated with higher post-ablation bleeding; leaves open effects on AF recurrence and thromboembolism.
Background Obesity has been identified as both a driving and aggravating factor in the pathogenesis of atrial fibrillation (AF). Obesity also has a significant impact on the treatment approaches for AF due to its influence on the pharmacokinetics of antiarrhythmic drugs and anticoagulation regimes. Objectives To analyze the ablation outcome and post-interventional management of anticoagulation in patients (pts) with obesity or severe obesity and atrial fibrillation treated with catheter ablation Methods This is a retrospective single-center analysis of 1306 consecutive patients who underwent ablation therapy for atrial fibrillation (AF) or left atrial tachycardia (AT) at a large tertiary center. Pts were divided into two groups according to their BMI, group 1 (BMI 30.0-39.9 kg/m²) and group 2 (>40 kg/m²). Clinical data were analyzed according to ablation success and post-interventional management of anticoagulation and statistical analysis was performed using RStudio. Results 325 pts (64% male) met the inclusion criteria (group 1 n=285, mean BMI 32.5 kg/m²; group 2 n=40, mean BMI 43.7 kg/m²). Most pts were treated for persistent AF or AT (71%), and 19% for paroxysmal AF or typical atrial flutter (10%). About half of the pts (n=150, 46%) received a 12-month follow-up (FU) visit, and 137/325 (42%) were followed for up to 55 months. 39.3% experienced arrhythmia recurrence within 12 months. There were no significant differences in the recurrence rate (52 pts (40.6%) in group 1, 7 (31.8%) in group 2 (p = 0.586)). Similarly, the long-term recurrence rate beyond 12 months was 41% in group 1 and 59.1% in group 2 (p = 0.167). Within the first 12 months, 39% of pts in group 1, and 32% of pts in group 2 required at least one re-ablation in order to obtain sinus rhythm at the 12-month FU visit. In both groups, the median CHA2DS2-VA-Score was 2 (Figure 1). Oral anticoagulation (OAC) discontinuation was comparable between the two groups (10.9% vs. 9.1%; p = 1.000; OR = 1.04, 95% CI 0.25-4.31). Notably, no thromboembolic event occurred in pts with a CHA2DS2-VA-Score <2, regardless of OAC status. The overall incidence of thromboembolic events did not differ significantly between the two groups (12.5% vs. 12.6%; p = 1.000; OR = 0.99, 95% CI 0.28-2.77), In contrast, the occurrence of bleeding events was higher in case of adipositas per magna compared to less severe adipositas (12.5% vs. 3.9%; p = 0.034; OR = 3.54, 95% CI 0.91-11.87). Most commonly, in group 2 urogenital bleeding occurred (Figure 2). Conclusion Our data show that overall there are no significant differences in the treatment success for obese and severely obese patients. Most notably, the efficacy of anticoagulation remains unaffected by severe overweight, and stopping the anticoagulation after ablation in severely obese patients seems beneficial due to comparable stroke incidence but a higher bleeding risk.
No takes yet. Share an insight, caveat, or question.
Bares et al. (2026) conducted a cohort in Atrial fibrillation or left atrial tachycardia with obesity (n=325). Severe obesity (BMI >40 kg/m²) vs. Obesity (BMI 30.0-39.9 kg/m²) was evaluated on Bleeding events (OR 3.54, 95% CI 0.91-11.87, p=0.034). Severe obesity (BMI >40 kg/m²) was associated with a higher risk of bleeding events compared to obesity after AF ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: